Methods: We performed a retrospective study of patients ≥18 years of age admitted to VUH with a culture-positive, monomicrobial, S. aureus orthopedic HW infection. Select ICD-10 codes related to orthopedic HW infections were used to identify potential patients. Exclusion criteria included concomitant bacteremia or polymicrobial infections. Patients with sterile site cultures obtained from August 2016-January 2017 were included in the pre-Alere® group and February 2017-September 2017 in the post-Alere® group. The primary outcome was time to appropriate antibiotic, defined as cefazolin or nafcillin for MSSA, and vancomycin for MRSA. Daptomycin and linezolid were acceptable alternatives in the case of prior vancomycin failure, or severe, documented reaction to vancomycin.
Results: ICD-10 codes identified a total of 331 patients, with 29 (8.7%) demonstrating monomicrobial S. aureus HW infections (52% MSSA). There were 11 (38%) and 18 (62%) patients in pre- and post-Alere® groups, respectively. Alere® results provided definitive methicillin susceptibility 31.9 (range 19.5-46.1) hours before standard culture results. Time to appropriate antibiotic was 41.8 hours less in post-Alere® group (p=0.009). Duration of empiric gram-negative coverage was significantly reduced in the post-Alere® group (p=0.029). Overall length of stay was unchanged between the groups (p=0.873).
Conclusion: Introduction of Alere® reduced time to appropriate therapy and reduced empiric gram negative coverage in patients being treated for orthopedic hardware infections.
P. Wright, None
M. Greene, None
G. Nelson, None